Authors: Sharon Salt, Editor
Catch up on our daily update from Day 1 here.
Catch up on our daily update from Day 2 here.
Catch up on our daily update from Day 3 here.
Pick of the posters
- Gatt A, Whitfield DR, Chambers D et al. A ‘triage’ system for identifying candidate compounds for repurposing as potential therapeutics for AD. The aim of this study was to validate the use of the connectivity map project (CMAP) bioinformatic approach to identify potential therapeutic compounds for clinical use. The researchers anticipate that this approach, which integrates in silico, in vitro and in vivo findings could identify compounds that may be repurposed to serve as Alzheimer’s therapeutics.
- Lynch SY, Kaplow J, Zhao J, Dhadda S, Luthman J, Albala B. Elenbecestat, a BACE inhibitor: results from a Phase II study in subjects with mild cognitive impairment and mild-to-moderate dementia due to Alzheimer’s disease. Phase I clinical studies of elenbecestat have demonstrated robust dose- and exposure-related effects of elenbecestat on plasma amyloid beta (Aβ)1-x and CSF Aβ(1-x), Aβ40, Aβ42, and BACE1 activity for doses ranging from 25 to 400 mg in healthy elderly subjects. This Phase II study was an 18-month, placebo-controlled study investigating the safety and efficacy of elenbecestat in MCI-to-moderate Alzheimer’s patients. Their conclusions revealed that elenbecestat was generally well tolerated with no unexpected safety concerns evident in the study.
- Day GS, Amtashar F, Yarbrough ML et al. Quantifying CSF biofluid biomarkers of neuronal injury, neuroinflammation and neurotransmission in antibody mediated encephalitis. The objective of this study was to measure CSF biomarkers of neuronal injury, neuroinflammation and synaptic function in antibody mediated encephalitides. They summarized that neuronal integrity was acutely maintained in antibody mediated encephalitides patients and that neuroinflammatory markers were increased, whilst markers of synaptic function were decreased. In conclusion, they stated that biofluid biomarkers validated in patients with neurodegenerative diseases can inform antibody mediated encephalitides pathogenesis and may predict outcomes in recovering patients.
Today at our booth
Today was our last day exhibiting at AAIC 2018 and it’s been a fantastic conference overall – we’re already excited for next year’s AAIC 2019 conference! If you’re an early career researcher and are also attending, do let us know if you’d be interested in publishing a conference report for us. You can contact our Editor via email by clicking here.
Remember to sign up for Neuro Central, or follow our Twitter updates @Neuro_Central
Best of social media #AAIC18
Nice results from SPRINT-MIND! 15% reduction in MCI/dementia incidence w/ intensive bp control (<120 mm Hg vs standard=<140). Intensive control also reduced white matter lesion volume. Trial stopped after 3.3 yrs bc so successful, but cog data are after ~6 yrs follow up.
— Maria Glymour (@MariaGlymour) 25 July 2018
We know that air pollution particles can get into the brain – we don’t know whether this is linked to dementia. Early life exposure to air pollution may increase risk but only in combination with the effects of other life course risks
— Aoife Kiely (@A0ifeKiely) 25 July 2018